li_item_id stringlengths 7 30 | drug_name stringlengths 4 169 | li_drug_name stringlengths 4 169 ⌀ | li_form stringlengths 8 210 ⌀ | schedule_form stringlengths 21 261 ⌀ | brand_name stringlengths 3 88 ⌀ | program_code stringclasses 17 values | pbs_code stringlengths 3 6 | benefit_type_code stringclasses 4 values | caution_indicator stringclasses 2 values | note_indicator stringclasses 2 values | manner_of_administration stringclasses 25 values | maximum_prescribable_pack float64 0.08 200 ⌀ | maximum_quantity_units float64 1 2.1k ⌀ | number_of_repeats float64 0 140 ⌀ | organisation_id float64 7 2.49k ⌀ | manufacturer_code stringclasses 226 values | pack_size float64 1 1k ⌀ | pricing_quantity float64 1 1k ⌀ | pack_not_to_be_broken_ind stringclasses 2 values | claimed_price float64 0.75 2.53M ⌀ | determined_price float64 0.75 2.53M ⌀ | determined_qty stringclasses 2 values | safety_net_resupply_rule_days float64 4 50 ⌀ | safety_net_resup_rule_cnt_ind stringclasses 2 values | extemporaneous_indicator stringclasses 2 values | extemporaneous_standard stringclasses 14 values | doctors_bag_group_id float64 1 62 ⌀ | section100_only_indicator stringclasses 2 values | doctors_bag_only_indicator stringclasses 2 values | brand_substitution_group_id float64 14.6k 29.7k ⌀ | brand_substitution_group_code stringclasses 2 values | supply_only_indicator stringclasses 2 values | supply_only_date stringclasses 9 values | non_effective_date stringclasses 3 values | weighted_avg_disclosed_price float64 | originator_brand_indicator stringclasses 2 values | paper_med_chart_eligible_ind stringclasses 2 values | elect_med_chart_eligible_ind stringclasses 2 values | hsptl_med_chart_eligible_ind stringclasses 2 values | paper_med_chart_duration float64 4 4 ⌀ | elect_med_chart_duration float64 6 6 ⌀ | hsptl_chart_acute_duration float64 12 12 ⌀ | hsptl_chart_sub_acute_duration float64 12 12 ⌀ | hsptl_chart_chronic_duration float64 12 12 ⌀ | pack_content float64 1 20k ⌀ | vial_content float64 1 15k ⌀ | infusible_indicator stringclasses 2 values | unit_of_measure stringclasses 6 values | continued_dispensing_flag stringclasses 2 values | continued_dispensing_emergency stringclasses 1 value | maximum_amount float64 2 30k ⌀ | formulary stringclasses 3 values | water_added_ind stringclasses 2 values | section_19a_expiry_date stringclasses 16 values | container_fee_type stringclasses 2 values | policy_applied_imdq60_base_flag stringclasses 2 values | policy_applied_imdq60_flag stringclasses 2 values | policy_applied_bio_sim_up_flag stringclasses 1 value | policy_applied_indig_phar_flag stringclasses 2 values | therapeutic_exemption_indicator stringclasses 2 values | premium_exemption_group_id float64 1.34k 1.34k ⌀ | doctors_bag_group_title stringclasses 1 value | therapeutic_group_id float64 1.34k 1.34k ⌀ | therapeutic_group_title stringclasses 1 value | advanced_notice_date stringclasses 3 values | supply_only_end_date stringclasses 8 values | first_listed_date stringdate 1991-08-01 00:00:00 2025-05-01 00:00:00 ⌀ | legal_unar_ind stringclasses 2 values | legal_car_ind stringclasses 2 values | schedule_code int64 3.67k 3.67k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10001J_14023_31078_31081_31083 | Rifaximin | Rifaximin | Tablet 550 mg | rifaximin 550 mg tablet, 56 | Xifaxan | GE | 10001J | A | N | Y | ORAL | 1 | 56 | 5 | 122 | NE | 56 | 56 | N | 394.14 | 394.14 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10003L_13467_29812_29815_29817 | Dabrafenib | Dabrafenib | Capsule 75 mg (as mesilate) | dabrafenib 75 mg capsule, 120 | Tafinlar | GE | 10003L | S | N | Y | ORAL | 1 | 120 | 5 | 25 | NV | 120 | 120 | N | 6,995.23 | 6,995.23 | N | 20 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10004M_7501_1327_5783_52398 | Sunitinib | Sunitinib | Capsule 12.5 mg | sunitinib 12.5 mg capsule, 28 | Sunitinib Sandoz | GE | 10004M | A | N | Y | ORAL | 1 | 28 | 2 | 90 | SZ | 28 | 28 | N | 513.55 | 513.55 | N | 20 | Y | N | null | null | N | N | 25,573 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-10-01 | N | N | 3,671 |
10004M_7501_1327_5783_7045 | Sunitinib | Sunitinib | Capsule 12.5 mg | sunitinib 12.5 mg capsule, 28 | Sutent | GE | 10004M | A | N | Y | ORAL | 1 | 28 | 2 | 69 | PF | 28 | 28 | N | 513.55 | 513.55 | N | 20 | Y | N | null | null | N | N | 25,573 | a | N | null | null | null | Y | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10005N_14031_31172_31177_31179 | Olmesartan + amlodipine + hydrochlorothiazide | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet, 30 | Sevikar HCT 20/5/12.5 | GE | 10005N | R | N | N | ORAL | 1 | 30 | 5 | 142 | AF | 30 | 30 | N | 8.36 | 5.57 | N | 20 | Y | N | null | null | N | N | 23,701 | a | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10005N_14031_31172_31177_48899 | Olmesartan + amlodipine + hydrochlorothiazide | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet, 30 | Olmekar HCT 20/5/12.5 | GE | 10005N | R | N | N | ORAL | 1 | 30 | 5 | 1,081 | RF | 30 | 30 | N | 5.57 | 5.57 | N | 20 | Y | N | null | null | N | N | 23,701 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2020-10-01 | N | N | 3,671 |
10005N_14031_31172_31177_49303 | Olmesartan + amlodipine + hydrochlorothiazide | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet, 30 | APO-Olmesartan/Amlodipine/HCTZ 20/5/12.5 | GE | 10005N | R | N | N | ORAL | 1 | 30 | 5 | 72 | TX | 30 | 30 | N | 5.57 | 5.57 | N | 20 | Y | N | null | null | N | N | 23,701 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2020-04-01 | N | N | 3,671 |
10005N_14031_31172_31177_54877 | Olmesartan + amlodipine + hydrochlorothiazide | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet, 30 | Olamlo HCT 20/5/12.5 | GE | 10005N | R | N | N | ORAL | 1 | 30 | 5 | 142 | AL | 30 | 30 | N | 5.57 | 5.57 | N | 20 | Y | N | null | null | N | N | 23,701 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2023-03-01 | N | N | 3,671 |
10007Q_14069_31262_31272_31274 | fluticasone propionate + formoterol | Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | fluticasone propionate 125 microgram/actuation + formoterol fumarate dihydrate 5 microgram/actuation inhalation, 120 actuations | flutiform 125/5 | GE | 10007Q | S | N | Y | INHALATION_BY_MOUTH | 1 | 1 | 5 | 134 | MF | 1 | 1 | Y | 24.54 | 24.54 | N | 20 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | null | Y | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10008R_14070_31262_31278_31280 | fluticasone propionate + formoterol | Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses | fluticasone propionate 250 microgram/actuation + formoterol fumarate dihydrate 10 microgram/actuation inhalation, 120 actuations | flutiform 250/10 | GE | 10008R | S | N | Y | INHALATION_BY_MOUTH | 1 | 1 | 5 | 134 | MF | 1 | 1 | Y | 35.44 | 35.44 | N | 20 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | null | Y | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10009T_7501_1327_5783_52398 | Sunitinib | Sunitinib | Capsule 12.5 mg | sunitinib 12.5 mg capsule, 28 | Sunitinib Sandoz | GE | 10009T | S | N | Y | ORAL | 1 | 28 | 5 | 90 | SZ | 28 | 28 | N | 513.55 | 513.55 | N | 20 | Y | N | null | null | N | N | 25,574 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-10-01 | N | N | 3,671 |
10009T_7501_1327_5783_7045 | Sunitinib | Sunitinib | Capsule 12.5 mg | sunitinib 12.5 mg capsule, 28 | Sutent | GE | 10009T | S | N | Y | ORAL | 1 | 28 | 5 | 69 | PF | 28 | 28 | N | 513.55 | 513.55 | N | 20 | Y | N | null | null | N | N | 25,574 | a | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10010W_10254_1327_5785_52407 | Sunitinib | Sunitinib | Capsule 50 mg | sunitinib 50 mg capsule, 28 | Sunitinib Sandoz | GE | 10010W | S | N | Y | ORAL | 1 | 28 | 5 | 90 | SZ | 28 | 28 | N | 2,092.68 | 2,092.68 | N | 20 | Y | N | null | null | N | N | 25,555 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-10-01 | N | N | 3,671 |
10010W_10254_1327_5785_54449 | Sunitinib | Sunitinib | Capsule 50 mg | sunitinib 50 mg capsule, 28 | ARX-Sunitinib | GE | 10010W | S | N | Y | ORAL | 1 | 28 | 5 | 1,908 | XT | 28 | 28 | N | 2,092.68 | 2,092.68 | N | 20 | Y | N | null | null | N | N | 25,555 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2022-09-01 | N | N | 3,671 |
10010W_10254_1327_5785_7047 | Sunitinib | Sunitinib | Capsule 50 mg | sunitinib 50 mg capsule, 28 | Sutent | GE | 10010W | S | N | Y | ORAL | 1 | 28 | 5 | 69 | PF | 28 | 28 | N | 2,092.68 | 2,092.68 | N | 20 | Y | N | null | null | N | N | 25,555 | a | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10011X_12926_28323_28324_28328 | Dapagliflozin | Dapagliflozin | Tablet 10 mg (as propanediol monohydrate) | dapagliflozin 10 mg tablet, 28 | Forxiga | GE | 10011X | S | N | Y | ORAL | 1 | 28 | 5 | 76 | AP | 28 | 28 | N | 36.61 | 36.61 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F1 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10012Y_14042_31242_31245_31247 | Ivabradine | Ivabradine | Tablet 5 mg (as hydrochloride) | ivabradine 5 mg tablet, 56 | Coralan | GE | 10012Y | S | N | Y | ORAL | 1 | 56 | 5 | 75 | SE | 56 | 56 | N | 31.03 | 31.03 | N | 20 | Y | N | null | null | N | N | 22,577 | a | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2013-12-01 | N | N | 3,671 |
10012Y_14042_31242_31245_46055 | Ivabradine | Ivabradine | Tablet 5 mg (as hydrochloride) | ivabradine 5 mg tablet, 56 | APO-Ivabradine | GE | 10012Y | S | N | Y | ORAL | 1 | 56 | 5 | 72 | TX | 56 | 56 | N | 31.03 | 31.03 | N | 20 | Y | N | null | null | N | N | 22,577 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2018-10-01 | N | N | 3,671 |
10012Y_14042_31242_31245_58372 | Ivabradine | Ivabradine | Tablet 5 mg (as hydrochloride) | ivabradine 5 mg tablet, 56 | IVABRADINE-WGR | GE | 10012Y | S | N | Y | ORAL | 1 | 56 | 5 | 2,410 | WG | 56 | 56 | N | 31.03 | 31.03 | N | 20 | Y | N | null | null | N | N | 22,577 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2024-09-01 | N | N | 3,671 |
10014C_9584_1305_5723_51489 | Erlotinib | Erlotinib | Tablet 150 mg (as hydrochloride) | erlotinib 150 mg tablet, 30 | Erlotinib Sandoz | GE | 10014C | A | N | N | ORAL | 1 | 30 | 3 | 90 | SZ | 30 | 30 | N | 469.61 | 469.61 | N | 20 | Y | N | null | null | N | N | 24,897 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-04-01 | N | N | 3,671 |
10014C_9584_1305_5723_51646 | Erlotinib | Erlotinib | Tablet 150 mg (as hydrochloride) | erlotinib 150 mg tablet, 30 | Erlotinib APOTEX | GE | 10014C | A | N | N | ORAL | 1 | 30 | 3 | 72 | TX | 30 | 30 | N | 469.61 | 469.61 | N | 20 | Y | N | null | null | N | N | 24,897 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-05-01 | N | N | 3,671 |
10014C_9584_1305_5723_59500 | Erlotinib | Erlotinib | Tablet 150 mg (as hydrochloride) | erlotinib 150 mg tablet, 30 | ERLOTINIB ARX | GE | 10014C | A | N | N | ORAL | 1 | 30 | 3 | 1,908 | XT | 30 | 30 | N | 469.61 | 469.61 | N | 20 | Y | N | null | null | N | N | 24,897 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2025-01-01 | N | N | 3,671 |
10015D_14170_1161_31502_31504 | Budesonide + formoterol | Budesonide with formoterol | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | budesonide 100 microgram/actuation + formoterol fumarate dihydrate 3 microgram/actuation inhalation, 120 actuations | Symbicort Rapihaler 100/3 | GE | 10015D | S | N | Y | INHALATION_BY_MOUTH | 2 | 2 | 5 | 76 | AP | 1 | 1 | N | 15.71 | 13.4 | N | 20 | N | N | null | null | N | N | 27,578 | a | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-01-01 | N | N | 3,671 |
10015D_14170_1161_31502_56565 | Budesonide + formoterol | Budesonide with formoterol | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | budesonide 100 microgram/actuation + formoterol fumarate dihydrate 3 microgram/actuation inhalation, 120 actuations | Rilast RAPIHALER 100/3 | GE | 10015D | S | N | Y | INHALATION_BY_MOUTH | 2 | 2 | 5 | 1,908 | XT | 1 | 1 | N | 13.4 | 13.4 | N | 20 | N | N | null | null | N | N | 27,578 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2023-08-01 | N | N | 3,671 |
10017F_22428_31353_31356_31358 | dressing foam with silicone | Dressing-foam with silicone | Dressings 10.3 cm x 10.3 cm, 10 | dressing foam with silicone 10.3 cm x 10.3 cm dressing, 10 | Allevyn Life 66801067 | R1 | 10017F | U | N | Y | FOR_EXTERNAL_USE | 1 | 1 | 0 | 100 | SN | 1 | 1 | Y | 56.87 | 56.87 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | null | N | null | null | N | N | N | N | N | null | null | null | null | null | null | 2014-01-01 | N | N | 3,671 |
10018G_14171_1161_31505_31507 | Budesonide + formoterol | Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | budesonide 200 microgram/actuation + formoterol fumarate dihydrate 6 microgram/actuation inhalation, 120 actuations | Symbicort Rapihaler 200/6 | GE | 10018G | S | N | Y | INHALATION_BY_MOUTH | 2 | 2 | 5 | 76 | AP | 1 | 1 | N | 24.37 | 22.06 | N | 20 | N | N | null | null | N | N | 27,585 | a | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-01-01 | N | N | 3,671 |
10018G_14171_1161_31505_56566 | Budesonide + formoterol | Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | budesonide 200 microgram/actuation + formoterol fumarate dihydrate 6 microgram/actuation inhalation, 120 actuations | Rilast RAPIHALER 200/6 | GE | 10018G | S | N | Y | INHALATION_BY_MOUTH | 2 | 2 | 5 | 1,908 | XT | 1 | 1 | N | 22.06 | 22.06 | N | 20 | N | N | null | null | N | N | 27,585 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2023-08-01 | N | N | 3,671 |
10019H_8909_1305_5722_51488 | Erlotinib | Erlotinib | Tablet 100 mg (as hydrochloride) | erlotinib 100 mg tablet, 30 | Erlotinib Sandoz | GE | 10019H | S | N | N | ORAL | 1 | 30 | 3 | 90 | SZ | 30 | 30 | N | 379.6 | 379.6 | N | 20 | Y | N | null | null | N | N | 24,894 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-04-01 | N | N | 3,671 |
10019H_8909_1305_5722_51645 | Erlotinib | Erlotinib | Tablet 100 mg (as hydrochloride) | erlotinib 100 mg tablet, 30 | Erlotinib APOTEX | GE | 10019H | S | N | N | ORAL | 1 | 30 | 3 | 72 | TX | 30 | 30 | N | 379.6 | 379.6 | N | 20 | Y | N | null | null | N | N | 24,894 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-05-01 | N | N | 3,671 |
10019H_8909_1305_5722_59685 | Erlotinib | Erlotinib | Tablet 100 mg (as hydrochloride) | erlotinib 100 mg tablet, 30 | ERLOTINIB ARX | GE | 10019H | S | N | N | ORAL | 1 | 30 | 3 | 1,908 | XT | 30 | 30 | N | 379.6 | 379.6 | N | 20 | Y | N | null | null | N | N | 24,894 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2025-03-01 | N | N | 3,671 |
10020J_8909_1305_5722_51488 | Erlotinib | Erlotinib | Tablet 100 mg (as hydrochloride) | erlotinib 100 mg tablet, 30 | Erlotinib Sandoz | GE | 10020J | A | N | N | ORAL | 1 | 30 | 3 | 90 | SZ | 30 | 30 | N | 379.6 | 379.6 | N | 20 | Y | N | null | null | N | N | 24,881 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-04-01 | N | N | 3,671 |
10020J_8909_1305_5722_51645 | Erlotinib | Erlotinib | Tablet 100 mg (as hydrochloride) | erlotinib 100 mg tablet, 30 | Erlotinib APOTEX | GE | 10020J | A | N | N | ORAL | 1 | 30 | 3 | 72 | TX | 30 | 30 | N | 379.6 | 379.6 | N | 20 | Y | N | null | null | N | N | 24,881 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-05-01 | N | N | 3,671 |
10020J_8909_1305_5722_59685 | Erlotinib | Erlotinib | Tablet 100 mg (as hydrochloride) | erlotinib 100 mg tablet, 30 | ERLOTINIB ARX | GE | 10020J | A | N | N | ORAL | 1 | 30 | 3 | 1,908 | XT | 30 | 30 | N | 379.6 | 379.6 | N | 20 | Y | N | null | null | N | N | 24,881 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2025-03-01 | N | N | 3,671 |
10021K_22429_31353_31371_31373 | dressing foam with silicone | Dressing-foam with silicone | Dressings 21 cm x 21 cm, 10 | dressing foam with silicone 21 cm x 21 cm dressing, 10 | Allevyn Life 66801070 | R1 | 10021K | U | N | Y | FOR_EXTERNAL_USE | 1 | 1 | 0 | 100 | SN | 1 | 1 | Y | 252.55 | 252.55 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | null | N | null | null | N | N | N | N | N | null | null | null | null | null | null | 2014-01-01 | N | N | 3,671 |
10022L_10263_1305_5724_51487 | Erlotinib | Erlotinib | Tablet 25 mg (as hydrochloride) | erlotinib 25 mg tablet, 30 | Erlotinib Sandoz | GE | 10022L | A | N | N | ORAL | 1 | 30 | 3 | 90 | SZ | 30 | 30 | N | 104.59 | 104.59 | N | 20 | Y | N | null | null | N | N | 24,909 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-04-01 | N | N | 3,671 |
10022L_10263_1305_5724_51644 | Erlotinib | Erlotinib | Tablet 25 mg (as hydrochloride) | erlotinib 25 mg tablet, 30 | Erlotinib APOTEX | GE | 10022L | A | N | N | ORAL | 1 | 30 | 3 | 72 | TX | 30 | 30 | N | 104.59 | 104.59 | N | 20 | Y | N | null | null | N | N | 24,909 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-05-01 | N | N | 3,671 |
10022L_10263_1305_5724_65904 | Erlotinib | Erlotinib | Tablet 25 mg (as hydrochloride) | erlotinib 25 mg tablet, 30 | ERLOTINIB ARX | GE | 10022L | A | N | N | ORAL | 1 | 30 | 3 | 1,908 | XT | 30 | 30 | N | 104.59 | 104.59 | N | 20 | Y | N | null | null | N | N | 24,909 | a | N | null | null | null | N | N | Y | Y | null | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2025-04-01 | N | N | 3,671 |
10023M_22430_31353_31366_31368 | dressing foam with silicone | Dressing-foam with silicone | Dressings 15.4 cm x 15.4 cm, 10 | dressing foam with silicone 15.4 cm x 15.4 cm dressing, 10 | Allevyn Life 66801069 | R1 | 10023M | U | N | Y | FOR_EXTERNAL_USE | 1 | 1 | 0 | 100 | SN | 1 | 1 | Y | 121.62 | 121.62 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | null | N | null | null | N | N | N | N | N | null | null | null | null | null | null | 2014-01-01 | N | N | 3,671 |
10025P_9584_1305_5723_51489 | Erlotinib | Erlotinib | Tablet 150 mg (as hydrochloride) | erlotinib 150 mg tablet, 30 | Erlotinib Sandoz | GE | 10025P | S | N | N | ORAL | 1 | 30 | 3 | 90 | SZ | 30 | 30 | N | 469.61 | 469.61 | N | 20 | Y | N | null | null | N | N | 24,914 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-04-01 | N | N | 3,671 |
10025P_9584_1305_5723_51646 | Erlotinib | Erlotinib | Tablet 150 mg (as hydrochloride) | erlotinib 150 mg tablet, 30 | Erlotinib APOTEX | GE | 10025P | S | N | N | ORAL | 1 | 30 | 3 | 72 | TX | 30 | 30 | N | 469.61 | 469.61 | N | 20 | Y | N | null | null | N | N | 24,914 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-05-01 | N | N | 3,671 |
10025P_9584_1305_5723_59500 | Erlotinib | Erlotinib | Tablet 150 mg (as hydrochloride) | erlotinib 150 mg tablet, 30 | ERLOTINIB ARX | GE | 10025P | S | N | N | ORAL | 1 | 30 | 3 | 1,908 | XT | 30 | 30 | N | 469.61 | 469.61 | N | 20 | Y | N | null | null | N | N | 24,914 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2025-01-01 | N | N | 3,671 |
10028T_10263_1305_5724_51487 | Erlotinib | Erlotinib | Tablet 25 mg (as hydrochloride) | erlotinib 25 mg tablet, 30 | Erlotinib Sandoz | GE | 10028T | S | N | N | ORAL | 1 | 30 | 3 | 90 | SZ | 30 | 30 | N | 104.59 | 104.59 | N | 20 | Y | N | null | null | N | N | 24,895 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-04-01 | N | N | 3,671 |
10028T_10263_1305_5724_51644 | Erlotinib | Erlotinib | Tablet 25 mg (as hydrochloride) | erlotinib 25 mg tablet, 30 | Erlotinib APOTEX | GE | 10028T | S | N | N | ORAL | 1 | 30 | 3 | 72 | TX | 30 | 30 | N | 104.59 | 104.59 | N | 20 | Y | N | null | null | N | N | 24,895 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2021-05-01 | N | N | 3,671 |
10028T_10263_1305_5724_65904 | Erlotinib | Erlotinib | Tablet 25 mg (as hydrochloride) | erlotinib 25 mg tablet, 30 | ERLOTINIB ARX | GE | 10028T | S | N | N | ORAL | 1 | 30 | 3 | 1,908 | XT | 30 | 30 | N | 104.59 | 104.59 | N | 20 | Y | N | null | null | N | N | 24,895 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2025-04-01 | N | N | 3,671 |
10029W_22431_31353_31361_31363 | dressing foam with silicone | Dressing-foam with silicone | Dressings 12.9 cm x 12.9 cm, 10 | dressing foam with silicone 12.9 cm x 12.9 cm dressing, 10 | Allevyn Life 66801068 | R1 | 10029W | U | N | Y | FOR_EXTERNAL_USE | 1 | 1 | 0 | 100 | SN | 1 | 1 | Y | 85.34 | 85.34 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | null | N | null | null | N | N | N | N | N | null | null | null | null | null | null | 2014-01-01 | N | N | 3,671 |
1002R_8397_129_1423_51618 | Aciclovir | Aciclovir | Eye ointment 30 mg per g, 4.5 g | aciclovir 3% eye ointment, 4.5 g | XOROX | GE | 1002R | R | N | N | APPLICATION_TO_THE_EYE | 1 | 1 | 0 | 118 | IX | 1 | 1 | Y | 14.08 | 14.08 | N | 4 | N | N | null | null | N | N | 22,959 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | null | N | N | N | N | N | null | null | null | null | null | null | 2021-08-01 | N | N | 3,671 |
1002R_8397_129_1423_51674 | Aciclovir | Aciclovir | Eye ointment 30 mg per g, 4.5 g | aciclovir 3% eye ointment, 4.5 g | ViruPOS | GE | 1002R | R | N | N | APPLICATION_TO_THE_EYE | 1 | 1 | 0 | 38 | AE | 1 | 1 | Y | 14.08 | 14.08 | N | 4 | N | N | null | null | N | N | 22,959 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | null | N | N | N | N | N | null | null | null | null | null | null | 2021-05-01 | N | N | 3,671 |
10032B_13948_30819_30835_30837 | Alogliptin + metformin | Alogliptin with metformin | Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride | alogliptin 12.5 mg + metformin hydrochloride 850 mg tablet, 56 | Nesina Met 12.5/850 | GE | 10032B | S | N | Y | ORAL | 1 | 56 | 5 | 104 | TK | 56 | 56 | N | 38.03 | 38.03 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-02-01 | N | N | 3,671 |
10033C_13947_30819_30832_30834 | Alogliptin + metformin | Alogliptin with metformin | Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride | alogliptin 12.5 mg + metformin hydrochloride 500 mg tablet, 56 | Nesina Met 12.5/500 | GE | 10033C | S | N | Y | ORAL | 1 | 56 | 5 | 104 | TK | 56 | 56 | N | 37.13 | 37.13 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-02-01 | N | N | 3,671 |
10034D_12927_185_29160_29162 | Budesonide | Budesonide | Rectal foam 2 mg per application, 14 applications, aerosol 16.8 g, 2 | budesonide 2 mg/application foam, 2 x 14 applications | Budenofalk | GE | 10034D | U | N | Y | RECTAL | 1 | 1 | 3 | 1,688 | FD | 1 | 1 | N | 127.07 | 127.07 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-02-01 | N | N | 3,671 |
10035E_13946_30819_30829_30831 | Alogliptin + metformin | Alogliptin with metformin | Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride | alogliptin 12.5 mg + metformin hydrochloride 1 g tablet, 56 | Nesina Met 12.5/1000 | GE | 10035E | S | N | Y | ORAL | 1 | 56 | 5 | 104 | TK | 56 | 56 | N | 38.39 | 38.39 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-02-01 | N | N | 3,671 |
10036F_14213_31583_31586_31588 | arachidonic acid and docosahexaenoic acid with carbohydrate | Arachidonic acid and docosahexaenoic acid with carbohydrate | Sachets of oral powder 4 g containing 200 mg arachidonic acid and 100 mg docosahexaenoic acid, 30 (keyomega) | arachidonic acid and docosahexaenoic acid with carbohydrate containing 200 mg arachidonic acid and 100 mg docosahexaenoic acid powder for oral liquid, 30 x 4 g sachets | keyomega | GE | 10036F | R | N | N | ORAL | 4 | 4 | 5 | 126 | VF | 1 | 1 | N | 72.68 | 72.68 | N | 20 | N | N | null | null | N | N | null | null | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10038H_14316_32112_32116_32118 | Linagliptin + metformin | Linagliptin with metformin | Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride | linagliptin 2.5 mg + metformin hydrochloride 500 mg tablet, 60 | Trajentamet | GE | 10038H | S | N | Y | ORAL | 1 | 60 | 5 | 71 | BY | 60 | 60 | N | 40.23 | 40.23 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10039J_14230_31595_31598_31600 | carbohydrates, fat, vitamins, minerals, trace elements and supplemented with arachidonic acid and docosahexaenoic acid | Carbohydrate, fat, vitamins, minerals and trace elements and supplemented with arachidonic acid and docosahexaenoic acid | Sachets containing oral powder 43 g, 30 (basecal 200) | carbohydrates, fat, vitamins, minerals, trace elements and supplemented with arachidonic acid and docosahexaenoic acid providing 200 kilocalories powder for oral liquid, 30 x 43 g sachets | basecal 200 | GE | 10039J | R | N | N | ORAL | 4 | 4 | 5 | 126 | VF | 1 | 1 | N | 93.96 | 93.96 | N | 20 | N | N | null | null | N | N | null | null | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
1003T_11093_129_1424_36965 | Aciclovir | Aciclovir | Tablet 200 mg | aciclovir 200 mg tablet, 25 | Aciclovir Sandoz | GE | 1003T | S | N | Y | ORAL | 2 | 50 | 0 | 90 | HX | 25 | 25 | N | 4.7 | 4.7 | N | 4 | N | N | null | null | N | N | 15,446 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2015-06-01 | N | N | 3,671 |
10041L_8372_25323_25329_25333 | Pazopanib | Pazopanib | Tablet 400 mg (as hydrochloride) | pazopanib 400 mg tablet, 60 | Votrient | GE | 10041L | S | N | Y | ORAL | 1 | 60 | 2 | 25 | NV | 60 | 30 | N | 4,085.88 | 2,042.94 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10042M_9052_25323_25324_25328 | Pazopanib | Pazopanib | Tablet 200 mg (as hydrochloride) | pazopanib 200 mg tablet, 90 | Votrient | GE | 10042M | S | N | Y | ORAL | 1 | 90 | 2 | 25 | NV | 90 | 30 | N | 3,064.41 | 1,021.47 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10043N_8372_25323_25329_25333 | Pazopanib | Pazopanib | Tablet 400 mg (as hydrochloride) | pazopanib 400 mg tablet, 60 | Votrient | GE | 10043N | S | N | Y | ORAL | 1 | 60 | 5 | 25 | NV | 60 | 30 | N | 4,085.88 | 2,042.94 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10044P_14315_32112_32128_32130 | Linagliptin + metformin | Linagliptin with metformin | Tablet containing 2.5 mg linagliptin with 1000 mg metformin hydrochloride | linagliptin 2.5 mg + metformin hydrochloride 1 g tablet, 60 | Trajentamet | GE | 10044P | S | N | Y | ORAL | 1 | 60 | 5 | 71 | BY | 60 | 60 | N | 41.45 | 41.45 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10045Q_14317_32112_32122_32124 | Linagliptin + metformin | Linagliptin with metformin | Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride | linagliptin 2.5 mg + metformin hydrochloride 850 mg tablet, 60 | Trajentamet | GE | 10045Q | S | N | Y | ORAL | 1 | 60 | 5 | 71 | BY | 60 | 60 | N | 41.01 | 41.01 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10046R_14210_1164_31608_31610 | Bimatoprost | Bimatoprost | Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30 | bimatoprost 0.03% eye drops, 30 x 0.4 mL ampoules | Lumigan PF | GE | 10046R | U | N | N | APPLICATION_TO_THE_EYE | 1 | 1 | 5 | 68 | VE | 1 | 1 | Y | 15.41 | 15.41 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | null | Y | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10047T_9052_25323_25324_25328 | Pazopanib | Pazopanib | Tablet 200 mg (as hydrochloride) | pazopanib 200 mg tablet, 90 | Votrient | GE | 10047T | S | N | Y | ORAL | 1 | 90 | 5 | 25 | NV | 90 | 30 | N | 3,064.41 | 1,021.47 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10048W_14312_32134_32150_32152 | Saxagliptin + metformin | Saxagliptin with metformin | Tablet (modified release) containing 2.5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | saxagliptin 2.5 mg + metformin hydrochloride 1 g modified release tablet, 56 | Kombiglyze XR 2.5/1000 | GE | 10048W | S | N | Y | ORAL | 1 | 56 | 5 | 76 | AP | 56 | 56 | N | 38.41 | 38.41 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
1004W_10416_126_1419_5981 | Acetazolamide | Acetazolamide | Tablet 250 mg | acetazolamide 250 mg tablet, 100 | Diamox | GE | 1004W | U | N | Y | ORAL | 1 | 100 | 3 | 1,081 | RW | 100 | 100 | N | 9.78 | 9.78 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2005-04-01 | N | N | 3,671 |
10051B_14313_32134_32144_32146 | Saxagliptin + metformin | Saxagliptin with metformin | Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | saxagliptin 5 mg + metformin hydrochloride 1 g modified release tablet, 28 | Kombiglyze XR 5/1000 | GE | 10051B | S | N | Y | ORAL | 1 | 28 | 5 | 76 | AP | 28 | 28 | N | 37.28 | 37.28 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10052C_8372_25323_25931_25933 | Pazopanib | Pazopanib | Tablet 400 mg (as hydrochloride) | pazopanib 400 mg tablet, 30 | Votrient | GE | 10052C | S | N | Y | ORAL | 1 | 30 | 5 | 25 | NV | 30 | 30 | N | 2,042.94 | 2,042.94 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10053D_14210_1164_31608_31610 | Bimatoprost | Bimatoprost | Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30 | bimatoprost 0.03% eye drops, 30 x 0.4 mL ampoules | Lumigan PF | GE | 10053D | U | N | Y | APPLICATION_TO_THE_EYE | 1 | 1 | 5 | 68 | VE | 1 | 1 | Y | 15.41 | 15.41 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | null | Y | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10054E_9052_25323_25928_25930 | Pazopanib | Pazopanib | Tablet 200 mg (as hydrochloride) | pazopanib 200 mg tablet, 30 | Votrient | GE | 10054E | S | N | Y | ORAL | 1 | 30 | 5 | 25 | NV | 30 | 30 | N | 1,021.47 | 1,021.47 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10055F_14314_32134_32138_32140 | Saxagliptin + metformin | Saxagliptin with metformin | Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 500 mg metformin hydrochloride | saxagliptin 5 mg + metformin hydrochloride 500 mg modified release tablet, 28 | Kombiglyze XR 5/500 | GE | 10055F | S | N | Y | ORAL | 1 | 28 | 5 | 76 | AP | 28 | 28 | N | 36.54 | 36.54 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | Y | N | null | CDL | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-03-01 | N | N | 3,671 |
10056G_8853_1373_5889_7175 | Tocilizumab | Tocilizumab | Concentrate for injection 200 mg in 10 mL | tocilizumab 200 mg/10 mL injection, 10 mL vial | Actemra | HB | 10056G | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 203.73 | 203.73 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10057H_11574_1167_5317_38268 | Infliximab | Infliximab | Powder for I.V. infusion 100 mg | infliximab 100 mg injection, 1 vial | Inflectra | HS | 10057H | S | N | Y | INJECTION | 5 | 5 | 1 | 69 | PF | 1 | 1 | N | 186.16 | 186.16 | N | 4 | N | N | null | null | N | N | 20,386 | a | N | null | null | null | N | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2015-12-01 | N | Y | 3,671 |
10057H_11574_1167_5317_41027 | Infliximab | Infliximab | Powder for I.V. infusion 100 mg | infliximab 100 mg injection, 1 vial | Renflexis | HS | 10057H | S | N | Y | INJECTION | 5 | 5 | 1 | 1,829 | OQ | 1 | 1 | N | 186.16 | 186.16 | N | 4 | N | N | null | null | N | N | 20,386 | a | N | null | null | null | N | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2017-08-01 | N | Y | 3,671 |
10057H_11574_1167_5317_6278 | Infliximab | Infliximab | Powder for I.V. infusion 100 mg | infliximab 100 mg injection, 1 vial | Remicade | HS | 10057H | S | N | Y | INJECTION | 5 | 5 | 1 | 63 | JC | 1 | 1 | N | 186.16 | 186.16 | N | 4 | N | N | null | null | N | N | 20,386 | a | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10058J_8853_1373_5889_7175 | Tocilizumab | Tocilizumab | Concentrate for injection 200 mg in 10 mL | tocilizumab 200 mg/10 mL injection, 10 mL vial | Actemra | HB | 10058J | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 203.73 | 203.73 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10059K_13916_30738_30742_30744 | Glycopyrronium | Glycopyrronium | Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) | glycopyrronium 50 microgram powder for inhalation, 30 capsules | seebri breezhaler | GE | 10059K | R | N | Y | INHALATION_BY_MOUTH | 1 | 30 | 5 | 25 | NV | 30 | 30 | N | 42.7 | 42.7 | N | 20 | Y | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | N | 3,671 |
10060L_8855_1373_5890_7176 | Tocilizumab | Tocilizumab | Concentrate for injection 400 mg in 20 mL | tocilizumab 400 mg/20 mL injection, 20 mL vial | Actemra | HS | 10060L | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 405.39 | 405.39 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10061M_7360_1385_5923_7212 | Denosumab | Denosumab | Injection 120 mg in 1.7 mL | denosumab 120 mg/1.7 mL injection, 1.7 mL vial | Xgeva | GE | 10061M | S | N | Y | INJECTION | 1 | 1 | 5 | 43 | AN | 1 | 1 | N | 401.85 | 401.85 | N | 20 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | N | 3,671 |
10062N_12690_1083_28137_37284 | Temozolomide | Temozolomide | Capsule 180 mg | temozolomide 180 mg capsule, 5 | APO-Temozolomide | GE | 10062N | R | N | Y | ORAL | 3 | 15 | 2 | 72 | TX | 5 | 5 | N | 99.7 | 99.7 | N | 4 | N | N | null | null | N | N | 20,168 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2015-07-01 | N | N | 3,671 |
10062N_12690_1083_28137_47751 | Temozolomide | Temozolomide | Capsule 180 mg | temozolomide 180 mg capsule, 5 | Temozolomide Juno | GE | 10062N | R | N | Y | ORAL | 3 | 15 | 2 | 1,040 | JX | 5 | 5 | N | 99.7 | 99.7 | N | 4 | N | N | null | null | N | N | 20,168 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2019-07-01 | N | N | 3,671 |
10064Q_8855_1373_5890_7176 | Tocilizumab | Tocilizumab | Concentrate for injection 400 mg in 20 mL | tocilizumab 400 mg/20 mL injection, 20 mL vial | Actemra | HB | 10064Q | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 405.39 | 405.39 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10066T_13919_15597_30773_30775 | Tobramycin | Tobramycin | Capsule containing powder for oral inhalation 28 mg (for use in podhaler) | tobramycin 28 mg powder for inhalation, 224 capsules | TOBI podhaler | GE | 10066T | S | N | Y | INHALATION_BY_MOUTH | 1 | 224 | 0 | 837 | GO | 224 | 224 | N | 2,282.85 | 2,282.85 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | N | 3,671 |
10067W_11574_1167_5317_38268 | Infliximab | Infliximab | Powder for I.V. infusion 100 mg | infliximab 100 mg injection, 1 vial | Inflectra | HB | 10067W | S | N | Y | INJECTION | 5 | 5 | 1 | 69 | PF | 1 | 1 | N | 186.16 | 186.16 | N | 4 | N | N | null | null | N | N | 20,396 | a | N | null | null | null | N | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2015-12-01 | N | Y | 3,671 |
10067W_11574_1167_5317_41027 | Infliximab | Infliximab | Powder for I.V. infusion 100 mg | infliximab 100 mg injection, 1 vial | Renflexis | HB | 10067W | S | N | Y | INJECTION | 5 | 5 | 1 | 1,829 | OQ | 1 | 1 | N | 186.16 | 186.16 | N | 4 | N | N | null | null | N | N | 20,396 | a | N | null | null | null | N | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2017-08-01 | N | Y | 3,671 |
10067W_11574_1167_5317_6278 | Infliximab | Infliximab | Powder for I.V. infusion 100 mg | infliximab 100 mg injection, 1 vial | Remicade | HB | 10067W | S | N | Y | INJECTION | 5 | 5 | 1 | 63 | JC | 1 | 1 | N | 186.16 | 186.16 | N | 4 | N | N | null | null | N | N | 20,396 | a | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10068X_12337_1373_5891_7177 | Tocilizumab | Tocilizumab | Concentrate for injection 80 mg in 4 mL | tocilizumab 80 mg/4 mL injection, 4 mL vial | Actemra | HS | 10068X | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 82.19 | 82.19 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10069Y_13910_30628_30629_30633 | Panitumumab | Panitumumab | Solution concentrate for I.V. infusion 100 mg in 5 mL | panitumumab 100 mg/5 mL injection, 5 mL vial | Vectibix | IN | 10069Y | S | N | Y | INJECTION | null | null | 5 | 43 | AN | 1 | 1 | N | 450.42 | 450.42 | Y | 4 | N | N | null | null | Y | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | 100 | 100 | Y | mg | N | N | 720 | F1 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | N | 3,671 |
10069Y_13911_30628_30636_30638 | Panitumumab | Panitumumab | Solution concentrate for I.V. infusion 400 mg in 20 mL | panitumumab 400 mg/20 mL injection, 20 mL vial | Vectibix | IN | 10069Y | S | N | Y | INJECTION | null | null | 5 | 43 | AN | 1 | 1 | N | 1,801.67 | 1,801.67 | Y | 4 | N | N | null | null | Y | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | 400 | 400 | Y | mg | N | N | 720 | F1 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-08-01 | N | N | 3,671 |
10071C_8853_1373_5889_7175 | Tocilizumab | Tocilizumab | Concentrate for injection 200 mg in 10 mL | tocilizumab 200 mg/10 mL injection, 10 mL vial | Actemra | HS | 10071C | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 203.73 | 203.73 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10072D_8855_1373_5890_7176 | Tocilizumab | Tocilizumab | Concentrate for injection 400 mg in 20 mL | tocilizumab 400 mg/20 mL injection, 20 mL vial | Actemra | HB | 10072D | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 405.39 | 405.39 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10073E_12337_1373_5891_7177 | Tocilizumab | Tocilizumab | Concentrate for injection 80 mg in 4 mL | tocilizumab 80 mg/4 mL injection, 4 mL vial | Actemra | HS | 10073E | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 82.19 | 82.19 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10074F_13919_15597_30773_30775 | Tobramycin | Tobramycin | Capsule containing powder for oral inhalation 28 mg (for use in podhaler) | tobramycin 28 mg powder for inhalation, 224 capsules | TOBI podhaler | GE | 10074F | S | N | Y | INHALATION_BY_MOUTH | 1 | 224 | 2 | 837 | GO | 224 | 224 | N | 2,282.85 | 2,282.85 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | Y | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | N | 3,671 |
10076H_14339_895_32226_32228 | Nicotine | Nicotine | Transdermal patch 39.4 mg | nicotine 25 mg/16 hours patch, 28 | nicorette 16hr Invisipatch | GE | 10076H | R | N | Y | TRANSDERMAL | 1 | 28 | 2 | 107 | JT | 28 | 28 | N | 35.23 | 35.23 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F1 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | N | 3,671 |
10077J_12337_1373_5891_7177 | Tocilizumab | Tocilizumab | Concentrate for injection 80 mg in 4 mL | tocilizumab 80 mg/4 mL injection, 4 mL vial | Actemra | HB | 10077J | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 82.19 | 82.19 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10078K_8855_1373_5890_7176 | Tocilizumab | Tocilizumab | Concentrate for injection 400 mg in 20 mL | tocilizumab 400 mg/20 mL injection, 20 mL vial | Actemra | HS | 10078K | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 405.39 | 405.39 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
10079L_8853_1373_5889_7175 | Tocilizumab | Tocilizumab | Concentrate for injection 200 mg in 10 mL | tocilizumab 200 mg/10 mL injection, 10 mL vial | Actemra | HS | 10079L | A | N | Y | INJECTION | 1 | 1 | 0 | 102 | RO | 1 | 1 | N | 203.73 | 203.73 | N | 4 | N | N | null | null | N | N | null | null | N | null | null | null | Y | N | N | Y | null | null | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | injectable | N | N | N | N | N | null | null | null | null | null | null | 2014-04-01 | N | Y | 3,671 |
1007B_11093_129_1426_36966 | Aciclovir | Aciclovir | Tablet 200 mg | aciclovir 200 mg tablet, 90 | Aciclovir Sandoz | GE | 1007B | S | N | Y | ORAL | 1 | 90 | 5 | 90 | HX | 90 | 25 | N | 16.92 | 4.7 | N | 20 | Y | N | null | null | N | N | 19,702 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2015-06-01 | N | N | 3,671 |
1007B_11093_129_1426_45635 | Aciclovir | Aciclovir | Tablet 200 mg | aciclovir 200 mg tablet, 90 | APO-Aciclovir | GE | 1007B | S | N | Y | ORAL | 1 | 90 | 5 | 72 | TX | 90 | 25 | N | 16.92 | 4.7 | N | 20 | Y | N | null | null | N | N | 19,702 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2018-08-01 | N | N | 3,671 |
1007B_11093_129_1426_47933 | Aciclovir | Aciclovir | Tablet 200 mg | aciclovir 200 mg tablet, 90 | Aciclovir APOTEX | GE | 1007B | S | N | Y | ORAL | 1 | 90 | 5 | 72 | TY | 90 | 25 | N | 16.92 | 4.7 | N | 20 | Y | N | null | null | N | N | 19,702 | a | N | null | 2025-07-01 | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | 2025-04-01 | null | 2019-08-01 | N | N | 3,671 |
1007B_11093_129_1426_58260 | Aciclovir | Aciclovir | Tablet 200 mg | aciclovir 200 mg tablet, 90 | ARX-ACICLOVIR | GE | 1007B | S | N | Y | ORAL | 1 | 90 | 5 | 1,908 | XT | 90 | 25 | N | 16.92 | 4.7 | N | 20 | Y | N | null | null | N | N | 19,702 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2024-07-01 | N | N | 3,671 |
1007B_11093_129_1426_58629 | Aciclovir | Aciclovir | Tablet 200 mg | aciclovir 200 mg tablet, 90 | ACICLOVIR-WGR | GE | 1007B | S | N | Y | ORAL | 1 | 90 | 5 | 2,410 | WG | 90 | 25 | N | 16.92 | 4.7 | N | 20 | Y | N | null | null | N | N | 19,702 | a | N | null | null | null | N | Y | Y | Y | 4 | 6 | 12 | 12 | 12 | null | null | N | null | N | N | null | F2 | N | null | other | N | N | N | N | N | null | null | null | null | null | null | 2024-09-01 | N | N | 3,671 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.